Warangalone_SDS_MedChemExpress

合集下载

一种治疗原发性肝癌的亚砷酸注射液及其制备方法[发明专利]

一种治疗原发性肝癌的亚砷酸注射液及其制备方法[发明专利]

专利名称:一种治疗原发性肝癌的亚砷酸注射液及其制备方法专利类型:发明专利
发明人:周晋,马满玲
申请号:CN200410042702.2
申请日:20040521
公开号:CN1698650A
公开日:
20051123
专利内容由知识产权出版社提供
摘要:本申请公开了一种治疗原发性肝癌,尤其是中晚期原发性肝癌的亚砷酸注射液及其制备方法,称取10-8000重量份三氧化二砷,加入到反应器中,加入质量为三氧化二砷质量100-500倍的注射用水,加热煮沸,用NaOH溶液调pH值为8-12,使三氧化二砷完全溶解,用盐酸调pH值为3-6,冷却至室温,然后加入注射用水至三氧化二砷重量浓度为10/1000000-8/1000,再用NaOH溶液和盐酸溶液调pH值为4.5-6.5,然后加入等渗物质,罐封,灭菌,即得亚砷酸注射液。

申请人:哈尔滨伊达药业有限公司
地址:150060 黑龙江省哈尔滨市高科技开发区平房集中区渤海路
国籍:CN
代理机构:北京科龙寰宇知识产权代理有限责任公司
代理人:孙皓晨
更多信息请下载全文后查看。

澳洲茄胺盐酸盐及其生产方法和在医药上的应用[发明专利]

澳洲茄胺盐酸盐及其生产方法和在医药上的应用[发明专利]

专利名称:澳洲茄胺盐酸盐及其生产方法和在医药上的应用专利类型:发明专利
发明人:刘良,刘芯晨,崔淑华
申请号:CN00129122.X
申请日:20000929
公开号:CN1345728A
公开日:
20020424
专利内容由知识产权出版社提供
摘要:一种具有较强抗癌、抗炎、平喘、活性的新的化合物澳洲茄胺盐酸盐,分子结构为如图:本发明还涉及澳洲茄胺盐酸盐的生产方法,以及该化合物做为一种中药一类新药源,并在抗癌、抗炎、平喘的口服、针剂两个剂型的医药上的应用。

申请人:刘良
地址:132011 吉林省吉林市北京路1号北华大学医学院有机化学教研室
国籍:CN
代理机构:吉林市达利专利事务所
代理人:杨天休
更多信息请下载全文后查看。

美国Medchemexpress化合物库(小分子库)_Medchemexpress_(MCE中国)

美国Medchemexpress化合物库(小分子库)_Medchemexpress_(MCE中国)

美国Medchemexpress化合物库(小分子库)-原装进口,现货供
应,提供组合定制服务
品牌:Medchemexpress (MCE)
保存条件:-20℃
供应商:MCE中国
数量:大量
保质期:2年
Size:
Pre-dissolved DMSO/Solid(Or dry solid)
100 uL/well (10 mM solution)
200 uL/well (10 mM solution)
MedChemExpress (MCE)专注于各种抑制剂、调节剂、API、天然产物及化合物库,总部位于美国新泽西。

MCE经过十年努力已成为全球生物活性小分子领域的一流供应商。

MedChemExpress(MCE)产品涵盖近20个热门研究领域,1000多个细分靶点,超过3000个现货抑制剂、拮抗剂和激动剂。

相关的应用成果已发表于Nature、Cell等国际知名杂志,在全球20余个国家地区设有代理机构。

上海皓元生物医药科技有限公司(MCE 中国) 是MedChemExpress (MCE) 亚洲总代理。

MCE化合物库涵盖20余种不同的类型,超过2500个化合物,进口原装,
现货供应,提供详实的生物活性信息、化学结构信息、质控图谱(NMR和HPLC 等)。

还可根据您的实际研究需要,为您度身定制任意组合、规格、布板的特殊化合物库。

/screening-libraries.html
现有特色化合物库有:。

α-硫辛酸预处理对大鼠肝脏缺血再灌注损伤的实验研究

α-硫辛酸预处理对大鼠肝脏缺血再灌注损伤的实验研究
s mp e t t e e a eh fh ma o y i — e sn sa n n . e uls Co p r d wih s a g o p, i h R r u a l swi he g n r lm tod o e t x ln h o i ti i g R s t m a e t h m r u n t e I g o p, t c iiy o J he a tvt fAIT,
Y n— o ,I i一 危 Q N Y n , uR n— u’ u b L e ; , I a e g i P .
A l t o i lfD l Clg , ai 70 0 C ia i ad pao f i e H s t ai oeeD l6 10 , h l n
中外 医 学 研 究
一 。
21 0 1年 1 第 9卷 0月
| 一- m 曩 | -
第2 9期 C N S N 0 E G E IA E E R H HIE E A D F R IN M D C LR S A C 菇雾 l l |_ 薯| | 譬 | | 。| l 曩誊| 誓 ≯曩≯≯。 曩| l ≯
ai r ra et ru ( c pe et n op 仅一I ru ) Ice i rpr s ngop I ru ) U igc m ehd ter s ee sdt b emoe o e d t m g J gop , hm a eef i ru (R gop . s l pm to ,h a r ue et dl fh A s uo n a
OL ‘ 。 ‘ 。
硫 辛 酸 预 处 理 对 大 鼠肝 脏 缺 血 再 灌 注 损 伤 的 实 验 研 究
齐崧 旭 谭 云波 李克志 秦 燕 刘仁 贵 大理 学院基础 医学院

《2024年两种制备方法对水飞蓟宾纳米混悬剂体内外行为的影响》范文

《2024年两种制备方法对水飞蓟宾纳米混悬剂体内外行为的影响》范文

《两种制备方法对水飞蓟宾纳米混悬剂体内外行为的影响》篇一一、引言随着现代医药科技的进步,纳米药物制剂的研发与应用逐渐成为医药领域的研究热点。

水飞蓟宾作为一种具有重要药用价值的成分,其纳米混悬剂的制备与体内外行为研究具有重要意义。

本文将探讨两种制备方法对水飞蓟宾纳米混悬剂体内外行为的影响,为进一步优化制备工艺及提高药物疗效提供理论依据。

二、材料与方法1. 材料水飞蓟宾、辅料、溶剂等。

2. 制备方法(1)方法一:采用XX制备技术,通过XX工艺流程制备水飞蓟宾纳米混悬剂。

(2)方法二:采用YY制备技术,通过YY工艺流程制备水飞蓟宾纳米混悬剂。

3. 实验方法(1)体内实验:通过动物实验,观察两种制备方法对水飞蓟宾纳米混悬剂的药动学、生物利用度及组织分布的影响。

(2)体外实验:采用细胞模型,评估两种制备方法对水飞蓟宾纳米混悬剂的释放性能、稳定性及细胞毒性的影响。

三、结果与讨论1. 体内实验结果(1)药动学:通过比较两种制备方法的水飞蓟宾纳米混悬剂在动物体内的药动学参数,发现方法二制备的混悬剂具有更高的口服生物利用度及更长的半衰期。

(2)生物利用度:方法二制备的水飞蓟宾纳米混悬剂在动物体内的生物利用度明显高于方法一,表明其具有更好的吸收性能。

(3)组织分布:两种制备方法的水飞蓟宾纳米混悬剂在动物体内的组织分布存在差异,方法二制备的混悬剂在靶组织中的浓度较高,具有更好的靶向性。

2. 体外实验结果(1)释放性能:通过细胞模型评估两种制备方法的释放性能,发现方法二制备的纳米混悬剂具有更好的缓释性能,能够更长时间地维持药物浓度。

(2)稳定性:两种制备方法的稳定性均较好,但在长时间储存后,方法二制备的纳米混悬剂表现出更好的稳定性。

(3)细胞毒性:两种制备方法的水飞蓟宾纳米混悬剂在细胞模型中的细胞毒性差异不大,均表现出较低的细胞毒性。

3. 讨论根据实验结果,可以得出以下结论:(1)方法二制备的水飞蓟宾纳米混悬剂在体内外均表现出较好的性能,具有更高的生物利用度、更好的靶向性、缓释性能及稳定性。

ICA_SDS_MedChemExpress

ICA_SDS_MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-15-2018Print Date:Jan.-15-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :ICACatalog No. :HY-22044CAS No. :3374-88-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:N–[4–(2–Pyridinyl)–2–thiazolyl]–2–pyridinamineFormula:C13H10N4SMolecular Weight:254.31CAS No. :3374-88-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light brown to brown (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

自身免疫性肝炎检测蛋白芯片及其试剂盒[发明专利]

自身免疫性肝炎检测蛋白芯片及其试剂盒[发明专利]

专利名称:自身免疫性肝炎检测蛋白芯片及其试剂盒专利类型:发明专利
发明人:穆海东,汪宁梅,穆宇豪,刘纲
申请号:CN200810204040.2
申请日:20081204
公开号:CN101750492A
公开日:
20100623
专利内容由知识产权出版社提供
摘要:本发明公开了一种用于自身免疫性肝炎检测的蛋白芯片及其试剂盒,可以同时检测
ANA(dsDNA、RNP、Sm、SS-A/Ro、SS-B/La、Scl-70、Jo-1)、SMA、LKM-1、SLA/LP、F-actin和AMA共12个免疫蛋白标志物。

克服了现有产品检测指标单一,检测指标不全面的缺陷,提供一种检测结果更全面、过程更简洁的检测方法。

申请人:上海裕隆生物科技有限公司
地址:200233 上海市钦州北路1089号50号楼4层
国籍:CN
更多信息请下载全文后查看。

作为促代谢型谷氨酸盐受体拮抗剂的炔哌嗪类[发明专利]

作为促代谢型谷氨酸盐受体拮抗剂的炔哌嗪类[发明专利]

专利名称:作为促代谢型谷氨酸盐受体拮抗剂的炔哌嗪类专利类型:发明专利
发明人:L·爱德华兹,M·伊萨克,A·斯拉西,孙光日,P·多夫,E·阿泽尔
申请号:CN200680028453.9
申请日:20060804
公开号:CN101248076A
公开日:
20080820
专利内容由知识产权出版社提供
摘要:本发明涉及式I化合物或其药学上可接受的盐或溶剂化物:其中Ar1、A、B、R1、m和n如说明书中所定义。

本发明还包括药物组合物及其用途、制备化合物的方法以及治疗mGluR 5介导的疾病的方法。

申请人:阿斯利康(瑞典)有限公司
地址:瑞典南泰利耶
国籍:SE
代理机构:中国专利代理(香港)有限公司
更多信息请下载全文后查看。

核磁共振波谱分析澳洲茄胺盐酸盐

核磁共振波谱分析澳洲茄胺盐酸盐

核磁共振波谱分析澳洲茄胺盐酸盐
宋见喜;高凌;姜爽
【期刊名称】《吉林化工学院学报》
【年(卷),期】2010(027)003
【摘要】用核磁共振波谱表征了澳洲茄胺盐酸盐,结果表明澳洲茄胺盐酸盐与澳洲茄胺核磁共振波谱相似.
【总页数】3页(P27-29)
【作者】宋见喜;高凌;姜爽
【作者单位】北华大学化学与生物学院,吉林,吉林,132013;北华大学林学院,吉林,吉林,132013;北华大学药学院,吉林,吉林,132013
【正文语种】中文
【中图分类】O657.2
【相关文献】
1.龙葵制剂中澳洲茄胺盐酸盐含量测定 [J], 李立英;孙丽光;刘良
2.澳洲茄胺盐酸盐注射剂对小鼠Lewis肺癌抑瘤作用研究 [J], 李富仁;丑莉莉;刘良
3.澳洲茄胺盐酸盐对小鼠肝癌H22抑制作用研究 [J], 李富仁;丑莉莉;刘良
4.紫外分光光度法测定澳洲茄胺盐酸盐含量 [J], 李立英
5.澳洲茄胺盐酸盐的质量控制 [J], 李立英;樊俊恒;刘良
因版权原因,仅展示原文概要,查看原文内容请购买。

水飞蓟宾纳米混悬剂的制备及大鼠体内药动学研究

水飞蓟宾纳米混悬剂的制备及大鼠体内药动学研究

水飞蓟宾纳米混悬剂的制备及大鼠体内药动学研究汪巍;赵暖;栾立标;韦琼华【期刊名称】《抗感染药学》【年(卷),期】2009(6)3【摘要】目的:探讨静脉注射用水飞蓟宾纳米混悬剂的制备,并评价其大鼠静注给药后的药动学。

方法:通过对水飞蓟宾纳米混悬剂理化性质及稳定性的评价,考察水飞蓟宾纳米混悬剂的制备方法、处方工艺,并以溶液剂为参照考察其在大鼠体内的药动学行为。

结果:水飞蓟宾纳米混悬剂的平均粒径是(268.90±9.20)nm,多分散性为0.22±0.12。

水飞蓟宾溶液剂及纳米混悬剂的药时曲线下面积分别为(34.92±0.98)μg·h·mL-1和(57.12±3.20)μg·h·mL-1,消除半衰期(t1/2)分别为(3.05±0.06)h和(6.14±0.42)h。

结论:制备的水飞蓟宾纳米混悬剂理化性质比较稳定,与溶?液剂相比,延长了药物在体内的驻留时间,具有一定的缓释效果。

【总页数】5页(P153-157)【关键词】水飞蓟宾;纳米混悬剂;自微乳化;高速分散;药动学【作者】汪巍;赵暖;栾立标;韦琼华【作者单位】中国药科大学药学院,药剂教研室【正文语种】中文【中图分类】R969.1;R944【相关文献】1.水飞蓟宾自微乳化胶囊剂的制备及大鼠体内药动学 [J], 丁沐淦;龙晓英;陈莉;何琳2.水飞蓟宾口服亚微乳剂的制备及大鼠体内药动学研究 [J], 高朝阳;李娟;芦霜3.水飞蓟宾-丹参素钠复方注射剂中水飞蓟宾和丹参素在大鼠体内的药动学研究 [J], 程凌飞;褚扬;万梅绪;马晓慧;张兰兰;陈建明;郭治昕;闫希军4.水飞蓟宾纳米乳的制备及家兔体内药动学 [J], 宋梅;平其能;吴正红因版权原因,仅展示原文概要,查看原文内容请购买。

迈瑞三羟甲基氨基甲烷用途

迈瑞三羟甲基氨基甲烷用途

迈瑞三羟甲基氨基甲烷用途迈瑞三羟甲基氨基甲烷,也简称为MCHA,是一种有机化合物,常用作添加剂和基础材料。

以下是迈瑞三羟甲基氨基甲烷的一些主要用途:1. 医药领域:迈瑞三羟甲基氨基甲烷是合成多种药物的重要原料之一。

它可以通过化学反应与其他药物分子结合,形成稳定的化合物。

这些药物可以用于治疗多种疾病,如高血压、心脏病、癌症等。

同时,迈瑞三羟甲基氨基甲烷还可以作为药物的缓释剂,帮助增加药物的持续释放时间,提高其疗效。

2. 化妆品和护肤品:迈瑞三羟甲基氨基甲烷可以用作化妆品和护肤品的抗菌剂。

护肤品中常常需要抑制细菌和真菌的生长,迈瑞三羟甲基氨基甲烷可以起到这样的作用。

它能有效抑制细菌的繁殖,保持产品的新鲜和卫生。

3. 食品和饮料加工:在食品和饮料加工过程中,迈瑞三羟甲基氨基甲烷可以被用作酸度调节剂和稳定剂。

它能够调整食品和饮料的酸碱度,增加产品的稳定性,延长其保质期。

除此之外,迈瑞三羟甲基氨基甲烷还可以用于凝固剂的制备,如果冻、布丁等。

4. 工业领域:迈瑞三羟甲基氨基甲烷在工业上还有一些重要的应用。

例如,它可以用作生物染料和感光剂的原料,用于印刷和光敏材料的制备。

此外,迈瑞三羟甲基氨基甲烷还可以用作合成树脂和聚合物的交联剂,提高材料的强度和耐磨性。

5. 化学实验室:迈瑞三羟甲基氨基甲烷常常被用于化学实验室。

它可以用作中和剂和缓冲液的配制。

在实验过程中,加入适量的迈瑞三羟甲基氨基甲烷可以调整试剂溶液的酸碱度,保持反应的稳定性。

此外,迈瑞三羟甲基氨基甲烷还可以用作染色剂的定性和定量分析。

总结起来,迈瑞三羟甲基氨基甲烷是一种多功能的有机化合物,在医药、化妆品、食品、饮料、工业和化学实验室等领域都有重要的应用。

它可以用来合成药物、抗菌剂、酸度调节剂和稳定剂,同时还可以用于制备染料、感光剂、交联剂等。

通过这些应用,迈瑞三羟甲基氨基甲烷为各行各业提供了一种重要的化学材料。

注射用海参糖胺聚糖异常毒性方法学研究王宗尉

注射用海参糖胺聚糖异常毒性方法学研究王宗尉

注射用海参糖胺聚糖异常毒性方法学研究王宗尉发布时间:2021-10-21T07:28:47.968Z 来源:《中国蒙医药》2021年第4期作者:王宗尉肖佳音李庆忠[导读] 制定其异常毒性标准检查项完善海参糖胺聚糖的安全性评价标准对于保障其临床使用具有重要意义。

黑龙江省药品检验研究中心黑龙江省哈尔滨市 150088【摘要】目的建立注射用海参糖胺聚糖异常毒性检查法。

方法:参考《中国药典》2015年版四部中《注射剂安全性检查法应用指导原则》,通过求得注射用海参糖胺聚糖静脉注射的LD50及其95%可信限,确定异常毒性检查限值。

结果本品静脉注射的LD50为189.4mg/kg,95%可信限为239.0~139.8mg/kg,取可信限下限(139.8mg/kg)的1/4作为异常毒性检查限值,即小鼠尾静脉注射本品35mg/kg。

取本品用氯化钠注射液配制成浓度为1.4mg/ml的溶液,按《中国药典》2015年版四部1141异常毒性检查法依法检查,结果注射后全部小鼠状态正常,观察48小时无死亡。

结论可以采用35mg/kg剂量作为本品异常毒性检查限值对其进行检查。

海参(Sea cucumber)是棘皮动物门海参纲的无脊椎动物,海参糖胺聚糖是从海参体壁中提取的一种多糖,其在抗肿瘤、抗血栓等方面具有良好的药用价值和发展前景[1][2]。

制定其异常毒性标准检查项完善海参糖胺聚糖的安全性评价标准对于保障其临床使用具有重要意义。

1 实验材料1.1 试药氯化钠注射液(哈尔滨三联药业股份有限公司,批号150324E2,规格500ml:4.5g);注射用海参糖胺聚糖(哈尔滨红豆杉生物制药有限公司提供,批号20161101,20161102,20161103,规格10mg/瓶)1.2 实验动物昆明种小鼠,清洁级,80只,雌性各半,体重18~22g,动物来源:长春市亿斯实验动物技术有限责任公司,生产许可证:SCXK(吉)2016-0004。

加巴喷汀原料中残留溶剂测定方法验证

加巴喷汀原料中残留溶剂测定方法验证

加巴喷汀原料中残留溶剂测定方法验证
魏俊卿;张萌;赵东明
【期刊名称】《河北化工》
【年(卷),期】2014(037)008
【摘要】加巴喷汀是美国Warner-Lanbert公司首先开发的抗癫痫药,是γ-氨基丁酸(GABA)的衍生物,于1993年首次在英国上市.其生产中的残留溶媒包括二氯甲烷、甲醇、乙醇、乙酸乙酯和异丙醇应进行严格控制.使用气相色谱法,采用顶空进样,参照ICH中Q3C对残留溶剂的要求,对加巴喷汀中的残留溶媒分析方法进行验证.验
证结果表明,本方法精密度高,线性良好,能够满足药品质量控制的需要.
【总页数】3页(P87-89)
【作者】魏俊卿;张萌;赵东明
【作者单位】石药集团欧意药业研究所,河北石家庄050000;石药集团欧意药业研
究所,河北石家庄050000;石药集团欧意药业研究所,河北石家庄050000
【正文语种】中文
【中图分类】TQ460.7
【相关文献】
1.泛硫乙胺原料中残留溶剂测定方法学研究 [J], 林丽琴;杨直;石云峰;潘云雪
2.三氯苯达唑中有机溶剂残留量测定方法学验证 [J], 韩加怡;郑国钢
3.有机溶剂残留量测定方法的验证 [J], 何卫民
4.两性霉素B中三乙胺残留溶剂测定方法验证 [J], 邓菲;党岳;高峥;李国俊
5.头孢唑肟钠中残留溶剂乙醇、丙酮含量测定方法验证 [J], 褚良鸥
因版权原因,仅展示原文概要,查看原文内容请购买。

仁济医院最新研究成果获发明专利

仁济医院最新研究成果获发明专利

仁济医院最新研究成果获发明专利
佚名
【期刊名称】《上海交通大学学报:医学版》
【年(卷),期】2008(28)8
【总页数】1页(P1031-1031)
【关键词】仁济医院;发明专利;肿瘤坏死因子α受体;抗肝细胞坏死;上海交通大学;重点实验室;体内半衰期;消化内科
【正文语种】中文
【中图分类】R197;R95
【相关文献】
1.糖尿病最新5项研究成果获FDA批准 [J], 高弘杨
2.中国石油石油化工研究院研究成果获国家发明专利授权 [J],
3.上海交通大学医学院附属仁济医院发表分娩启动最新研究成果 [J],
4.嘉兴市郁氏丁烷气厂最新推出获美国发明专利的——无氟、无毒、无水香味丁烷气 [J],
5.双胞胎集团“防治猪流行性腹泻中草药提取物”研究成果获发明专利 [J],
因版权原因,仅展示原文概要,查看原文内容请购买。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-22-2018Print Date:Jan.-22-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :WarangaloneCatalog No. :HY-N1074CAS No. :4449-55-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:Scandenolone; Scandenone; WarangalonFormula:C25H24O5Molecular Weight:404.45CAS No. :4449-55-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

相关文档
最新文档